Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Drug Profile

Research programme: Rho signalling pathway inhibitors - BioAxone BioSciences

Alternative Names: BA 1016; BA 1037; BA 1049; BA 285; BA-1076; BA-207; BA-215; BA-240; Rhostatin™

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; BioAxone Therapeutic
  • Class Small molecules
  • Mechanism of Action Rho GTP-binding protein-inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cerebrovascular disorders; Spinal cord injuries
  • No development reported Glaucoma
  • Discontinued Cancer; Cancer metastases; Cardiovascular disorders; CNS trauma; Optic nerve disorders; Retinal disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glaucoma in USA
  • 15 May 2017 Preclinical trials in Spinal cord injuries in USA (unspecified route) (BioAxone BioSciences pipeline, May 2017)
  • 11 May 2017 BioAxone BioSciences plans to file an IND application for BA 1049 for Cerebral cavernous malformation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top